



# Creating Lasting Value

Investor Presentation – December 2025

NSE:SUNPHARMA | BSE:524715 |  
Bloomberg:SUNP IN | Reuters:SUN.BO

WWW.SUNPHARMA.COM

# Disclaimer



Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue" and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

1

**Revenue composition and growth highlights**

2

**Business operations**

3

**R&D & Manufacturing**

4

**Corporate Governance**

5

**Key Financials**

6

**Company history and key deals**

7

**Focus areas**

# Sun Pharma at a glance



## Leading global specialty generic company

### Global presence

Operates in over 100 countries

### Diversified business

Innovative Medicines, branded generics, generics & APIs

### Innovative Medicines

Fast growing. Focused therapy approach.

### US Generics

13<sup>th</sup> largest in US generics market##

### India

Largest pharma company in India\*\*

### Emerging Markets

Operating at scale in over 80 countries

### Rest of World

Expanding presence in Ex-US developed markets

### R&D

Global clinical trials. Early-stage novel R&D. Generic R&D

### 40 Manufacturing facilities

Manufacturing capabilities across injectables, sprays, ointments, creams, liquids, tablets and capsules

### Quality compliance

Several facilities approved by global regulators incl. USFDA


### Employees

43,000+ global employee base

## Source: IQVIA data for 12 months ended Oct 2025

\*\* As per AIOCD AWACS data for 12 months ended Sept 2025

# A diversified revenue base









# Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets.

# Impressive track record of growth



(All Figures in Rs Bn)


CAGR for FY10-FY25




# Strong profitability and return ratios




## Gross Margin #




## EBITDA Margin




## Adjusted Net Profit Margin




## ROCE



## ROE



## Market Cap (USD Bn)



# Gross margin= (Sales - Material Cost)/Sales\*100)

ROCE & ROE exclude one-time exceptional charges

ROCE = EBIT / Average of (Total Assets – Current Liabilities)

ROE = Net Profit / Average Shareholders Equity


(Market Cap as on 31st March)

# Best-in-class profitability




— Sun Pharma ■ Range of Top 9 Indian Pharma Cos. — Average


## Gross Margin



## EBITDA Margin



## Adjusted Net Profit Margin



Gross margin= (Net Sales – Material Cost) / Net Sales \* 100

#Top 9 Indian Pharma companies include Cipla, Dr. Reddy's, Aurobindo, Zydus Lifesciences, Torrent, Alkem Labs, Lupin, Mankind and Divis Lab.



# Business operations




# Snapshot of business operations



## US Formulations


- FY25 sales: Rs 162,403 mn
- Innovative Medicines & Generics. Over 600 approved products
- Large part of Innovative Medicines sales in the US.
- 13<sup>th</sup> largest generics company in US\*, strong pipeline



Geographical split

## India Formulations

- FY25 sales: Rs 169,230 mn
- Largest pharma company in India with 8.3% market share
- No.1 with 13 classes of prescribers



Revenue share

## Emerging Markets (EM) Formulations

- FY25 sales: Rs 94,160 mn
- Over 80 countries across 5 continents
- Romania, Russia, South Africa, Brazil & Mexico are focus markets

## Rest of World (RoW) Formulations

- FY25 sales: Rs 71,626 mn
- Western Europe, Canada, Japan, Israel, A&NZ+
- Innovative Medicines & Generics. Differentiated offering for hospitals

Note:

(1) As of Dec 18, 2025, using spot exchange rate of INR /USD = 90.28

# Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets.


\* Source: IQVIA data for 12 months ended Sept 2025

# Driving sustainable long term growth



- Achieve critical mass in key markets
- Embed sustainability practices in business
- Actionable targets on sustainability

- Increase contribution of Innovative and complex products
- Direct future investments towards differentiated products



# ESG Performance - FY 2024-25



## Environmental

### Energy

- 41% Energy sourced from renewable sources
- 21% reduction in absolute Scope 1 and Scope 2 emissions compared to baseline year 2020

### Water

- 25% reduction in absolute water consumption compared to baseline year 2020

### Waste

- 37% of hazardous waste and 96% of non-hazardous waste is diverted from disposal recycling, reusing and other recovery options



## Social

### Employee wellbeing

- 6,978 new hires
- 18.59% gender diversity
- 0 fatalities

### Corporate Social Responsibility

- INR 1,424 million spent on CSR activities
- Over 1 million lives touched in India through CSR initiatives



## Governance

### Corporate Governance

- 92.9% Average Board meeting attendance
- 62.5% Independent board directors\*
- 50% of Board Members specializing in pharmaceutical industry experience#

\*As on 31<sup>st</sup> March 2025

#Includes Executive & Non-Executive Directors



# Innovative Medicines



# Innovative Medicines highlights



## Building an Innovative Medicines business in select therapy areas

### Focused approach

Marketed products in Dermatology, Ophthalmology and Onco Dermatology

### Key growth driver

20% of sales in FY25 vs 7.3% of sales in FY18

### Wide portfolio

27 products marketed globally

### US market presence\*

US is a large part of global Innovative Medicines revenues

### Own commercial infrastructure

Own commercial infrastructure in the US and certain other markets

### Future engine

Internal R&D pipeline. Acquisitions and licensing to shore up portfolio

\*Innovative Medicines revenues are reported as part of businesses, including US, RoW and others

# Innovative Medicines portfolio



*For treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy*

- Long term clinical data shows that the significant response rate seen in 52 & 64 weeks were maintained over five years<sup>1</sup>
- Completed Phase-3 trials for Psoriatic Arthritis
- Current Markets: US, Australia, Japan, Canada, Europe (by partner Almirall) & China (by partner CMS holdings)
- Out licensed to Hikma for Middle East & North Africa

*• An oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata*

- At baseline, the average patient had only 13% scalp hair coverage. At week 24, one-third of those patients experienced 80% scalp hair coverage<sup>2</sup>
- Current Markets: US

*Topical treatment of acne vulgaris in patients 12 years of age and older*

- Results from two pivotal clinical trials showed favourable safety and efficacy data for WINLEVI in patients with acne aged 12 years and older<sup>3</sup>
- Current Markets: US, Canada and Australia

*For photodynamic therapy (treatment) of minimally to moderately thick actinic keratoses of the face or scalp, or actinic keratoses of the upper extremities*

- First and only PDT approved to treat the face and scalp as well as the upper arms, forearms, and hands<sup>4</sup>
- Current Markets: US

Source:

1, 2 & 3 Sun Press Release  
4 Levulan website

All brand names and trademarks are the property of their respective owners

# Innovative Medicines portfolio



*Treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.*

- ODOMZO was shown to shrink laBCC in almost 6 out of 10 patients (56%) in a clinical study. laBCC Patients were treated with ODOMZO® and followed for at least 18 months<sup>5</sup>
- Currently marketed in US, Canada, EU, Australia and Israel



*To increase tear production in patients with keratoconjunctivitis sicca (dry eye)*

- Phase 3 confirmatory study observed clinically and statistically significant improvements in tear production and ocular surface integrity in patients<sup>6</sup>
- Current Markets: US, Canada and India
- Out-licensed to CMS for Greater China in June 2019



*Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery*

- More than 2x as many patients treated with Bromsite® were inflammation-free at day 15 than those treated with vehicle and nearly 80% of patients treated with Bromsite® were pain-free at day 1 post surgery<sup>7</sup>
- Current Markets: US



*Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.*

- In clinical trials, XELPROS demonstrated reductions from baseline in intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension<sup>8</sup>
- Current Markets: US

Source:

5 Product Label  
6 Sun Press Release  
7 & 8 Product website

All brand names and trademarks are the property of their respective owners

# Innovative Medicines portfolio



*In combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).*

- YONSA® was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combination with methylprednisolone<sup>9</sup>
- Current Markets: US



*First and only product approved in the US for treating seizures in neonatal patients*

- NEOLEV2 study compared phenobarbital to levetiracetam in the first-line treatment of neonatal seizures. 24 hours following the administration, 73% vs. 25% were seizure-free in the respective groups<sup>10</sup>
- Current Markets: US



*For therapeutic solutions for long-term care (LTC) patients*

- Products using sprinkle technology for patients who have difficulty swallowing
- Sprinkle versions of metoprolol (cardiology), rosuvastatin (cardiology) & duloxetine (neuro-psychiatry)
- Current Markets: US



- *Treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater*
- After one 20-week course of ABSORICA therapy, 95% of patients didn't require additional isotretinoin treatment up to two years post-treatment<sup>11</sup>
- Current Markets: US

# Innovative Medicines pipeline




Candidate	Mechanism of Action	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
Unloxcyt	anti-PD-L1	metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC	██████████	██████████	██████████	██████████	██████████
Nidlegy™	Immunocytokines	melanoma & non- melanoma skin cancers	██████████	██████████	██████████	██████████	██████████
Ilumya	IL-23 Antagonist	psoriatic arthritis	██████████	██████████	██████████	██████████	██████████
Fibromun	Innovative anti-cancer immunotherapy	soft tissue sarcoma glioblastoma	██████████	██████████	██████████	██████████	██████████
MM-II	Liposomal intra-articular lubrication	pain in osteoarthritis	██████████	██████████	██████████	██████████	██████████
GL0034	GLP-1R Agonist	type 2 diabetes	██████████	██████████			

All candidates for global markets except Nidlegy™ where Sun is commercial partner for Europe, Australia & New Zealand. Nidlegy™ is a trademark of Philogen.

# Innovative Medicines Sales




## Innovative Medicines Sales (USD mn)




- US is the major contributor to Innovative Medicines revenues
- Global sales have grown by 23% CAGR since FY20
- Largest product Ilumya reported sales of \$681 Mn in FY25
- 27 Innovative Medicines marketed across the globe
- Pipeline of six New Active Substances in the development stage

# US Business



**31% of FY25  
Revenues**



# US highlights



Sizeable innovative portfolio/13<sup>th</sup> largest in US Generics\*

Dermatology segment

Ranked 2<sup>nd</sup> by prescriptions## in the US dermatology market

Comprehensive portfolio\*\*

Wide basket of 665 ANDAs & 71 NDAs filed, and 548 ANDAs & 57 NDAs approved across multiple therapies

Robust pipeline\*\*

117 ANDAs & 14 NDAs pending approval with USFDA

Market presence

Presence in Innovative medicines, Generics & OTC segments

Flexible manufacturing

Integrated manufacturer with onshore/ offshore capabilities

Versatile dosage forms

Liquids, Creams, Ointments, Gels, Sprays, Injectables, Tablets, Capsules, Drug-Device combination

\* Source: IQVIA data for 12 months ended Oct 2025

## Source: IQVIA data for 12 months ended Oct 2025

*\*\*All data as of 30-Sept-2025*

# Milestones in the US business



FY25

- Acquired Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company

FY24

- Acquired outstanding shares of Taro, now a 100% subsidiary of Sun

FY23

- Acquired Concert Pharma giving access to deuruxolitinib for alopecia areata
- Launched Sezaby in the US

FY22

Launched Winlevi in the US

FY20

Launched Cequa & Absorica LD in the US

FY19

- Launched Ilumya, Yonsa & Xelpros in the US
- Received USFDA approval for Cequa
- Launched Ready-to-Infuse INFUGEM™

FY18

- Launched Odomzo in the US
- Received USFDA approval for Ilumya

FY17

- Acquired Ocular Technologies giving access to Cequa for dry eye
- Acquired Odomzo, a branded oncology product from Novartis

FY13

Acquired DUSA providing entry into Innovative Medicines

FY10

Acquired Taro Pharma providing entry into US dermatology


FY98

Entry in the US through Caraco acquisition

# US business: revenue progression




Sales in Rs Bn




# ANDA & NDA pipeline



## ANDAs filed and approved (cumulative)




## NDA filed and approved (cumulative)



(All data as of 30-Sept-2025)

# India Business



**33% of FY25  
Revenues**

**INDIA'S NO. 1\***  
**PHARMA COMPANY**  
**ISN'T JUST A TITLE.**  
**IT'S A PROMISE TO CARE,**  
**EVERY DAY.**

\*As per FICCI PHARMA data for 12 months ended Mar 2004



# India highlights



## Largest Pharma company in India Pharma market

### Market position\*\*

Largest Pharma company in India with 8.3% market share

### Prescription ranking##

Ranked No. 1 by prescriptions with 13 classes of prescribers

### Chronic segment

Market leader in the chronic segment

### Acute segment

Strong positioning in the acute segment

### Product offering

Technically complex products and a complete therapy basket

### Strong brand positioning\*\*

31 brands in India's top 300 pharmaceutical brands

### De-risked growth\*\*

Top 10 Brands contribute approx. 16% of India revenues – low product concentration

### Sales strength


Over 15,000 strong field force\*

\*\* As per AIOCD AWACS data for 12 months ended Sept'25

## As per SMSRC data for Mar-Jun'25


\* As of Sept 30<sup>th</sup>, 2025

# Largest Pharma company in India




Source: AIOCD AWACS MAT Sept 2025

# India: revenue progression



## Therapeutic breadth\*\*



\*\* As per AIOCD AWACS MAT Sept 2025

# Leadership across therapeutic areas\*

Number 1 Ranking with 13 Doctor Categories\*



Specialist	Prescription Ranking			
	June '22	June '23	June '24	June '25
Psychiatrists	1	1	1	1
Neurologists	1	1	1	1
Cardiologists	1	1	1	1
Gastroenterologists	1	1	1	1
Diabetologists	1	1	1	1
Consulting Physicians	1	1	1	1
Dermatologists	1	1	1	1
Urologists	1	1	1	1
Chest Physicians	1	1	1	1
Nephrologists	1	1	1	1
ENT	1	1	1	1
Gynaecologists	2	2	1	1
Oncologists	2	3	2	1
Orthopaedic	1	2	2	2
Ophthalmologists	2	1	1	2
General surgeons	2	2	2	3


\*Ranks based on prescription share

Source-Strategic Marketing Solutions and Research Centre (SMSRC) Prescription Data

# India: Best-in-class field force productivity




## Sales per medical representative (Rs mn)




- Well trained and scientifically oriented sales representatives team with strong performance track record
- Highest field force productivity amongst key players in India
- Expanded sales force in FY21, FY23, FY24 & FY25 to enhance geographical & doctor reach and improve brand focus

# Emerging Markets



**18% of FY25  
Revenues**



# Emerging Markets highlights



## Leading Indian company in Emerging Markets

### Global footprint

Presence in over 80 countries

### Focus markets

Romania, Russia, South Africa, Brazil, Mexico

### Product portfolio

Extensive basket of branded generics

### Customer focus

Strong relationships with prescribers

### Sales force

Over 2,900 sales representatives across markets



### Opportunity

Favourable macroeconomics driving increased pharmaceutical consumption

### Local manufacturing

Manufacturing sites in Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria, Morocco and Russia

# Rest of World (Western Europe, Canada, Japan, ANZ, Israel & other markets)



# Rest of World highlights



## Amongst the leading Indian companies

Market presence	Western Europe, Canada, A&NZ, Japan, Israel and others
Product portfolio	Expanding basket includes innovative medicines, hospital & retail products
Focus	Development and commercialization of differentiated products
Diverse Sales model	<ul style="list-style-type: none"><li>• Distribution-led model for generics</li><li>• Own sales force for Innovative products</li></ul>
Local manufacturing	In Canada, Australia, Israel and Hungary + supplies from India facilities
Japan presence	<ul style="list-style-type: none"><li>• Acquired 14 established prescription brands from Novartis in 2016</li><li>• Acquired Pola Pharma in Japan in 2019</li><li>• Launched Ilumya in Japan in 2020</li></ul>
Canada presence	<ul style="list-style-type: none"><li>• Portfolio of Generics and Innovative Medicines</li><li>• Innovative Medicines - Launched Ilumya in 2021, Cequa in 2022 and Winlevi in 2023</li></ul>



# Global Consumer Healthcare



# Global Consumer Healthcare highlights



## An attractive opportunity

India

Amongst the leading consumer healthcare companies

Global presence

Presence in over 25+ countries

Markets of presence

India, Romania, South Africa, Nigeria, Myanmar, Ukraine, Poland, Thailand, Belarus, Kazakhstan, Nepal, Morocco, UAE, Oman etc.

Strong brand equity

Strong brand equity in 4 countries

Sales force

Promoted through dedicated sales force in each market

Strong positioning

Amongst top 10 consumer healthcare companies in India, Romania, Nigeria & Myanmar

# Active Pharmaceutical Ingredients (API)



# API highlights



## Backward integration has strategic importance

### Strategic importance

Backward integration provides cost competitiveness and supply reliability

### Customers

Large generic and innovator companies

### Product portfolio

Approximately 400+ APIs

### Pipeline development

10-20 APIs scaled up annually

### Regulatory approvals

402 DMF/CEP approvals & 532 DMF/CEP Filings to date

### Manufacturing

Across 14 facilities

# Research & Development



# Research & Development



Cumulative R&D spend of ~Rs 320 Bn to date

R&D spend

R&D spend at 6.2% of sales for FY25

Innovative Medicines R&D

Global development capabilities incl. clinical trials

Generic capabilities

Finished dosage development, biological support, chemistry and new drug development

Organization

Over 2,900 headcount globally across several R&D centers

IPR support

Strong team of intellectual property experts supporting R&D


Focus

Development of Innovative Medicines/complex products and non infringing formulations


# R&D investments



## R&D investments



## Filings and approvals



\*\* Excludes expired/abandoned patents

█ R&D investments (Rs Bn) █ R&D investments (% of sales)

(All data as of 30-Sept-2025)

# Global Manufacturing



# Global Manufacturing highlights



## World Class manufacturing infrastructure

### Extensive global footprint

40 manufacturing facilities across India, the Americas, Asia, Africa, Australia and Europe

### Integrated network

Vertically integrated network across six continents enables high quality, low cost and a quick market entry across the geographies

### Wide capabilities

One of the few companies with integrated manufacturing of oncology, hormones, peptides and steroidal drugs

### High quality

Many facilities approved by USFDA, UK MHRA, EMEA and other international regulatory authorities

### Dosage forms

Ability to manufacture a variety of dosage forms – Orals, Creams, Ointments, Injectables, Sprays, Liquids

# Manufacturing facilities



40 manufacturing sites

- Formulation
  - India: 12, US : 3
  - Canada, Hungary, Israel, Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria, Morocco and Russia: 1 each
  - Capacities available for a variety of finished dosages
- API
  - India : 9, Australia : 2, Israel : 1, US : 1, Hungary : 1

Orals	Injectables / Sterile	Topicals
<ul style="list-style-type: none"><li>▪ Tablets / Capsules</li><li>▪ Semisolids</li><li>▪ Liquids</li><li>▪ Suppository</li></ul>	<ul style="list-style-type: none"><li>▪ Vials</li><li>▪ Ampoules</li><li>▪ Pre-filled Syringes</li><li>▪ Gels</li><li>▪ Lyophilized Units</li></ul>	<ul style="list-style-type: none"><li>▪ Dry powder</li><li>▪ Eye drops</li><li>▪ MDI</li><li>▪ Aerosols</li></ul>

# Corporate governance



Sun Pharma's Board of Directors comprises a strong and balanced leadership, with four out of eight members serving as independent directors.



**Lead Independent Director**

**Dr. Pawan Goenka**  
Former MD & CEO of Mahindra & Mahindra Ltd. Recognized as leader and statesman of the India corporate sector



**Independent Director**

**Gautam B. Doshi**  
Professional with expertise in M&A, Taxation, Accounting & Corp. and Commercial Law



**Independent Director**


**Rama Bijapurkar**  
Independent management consultant & Professor of Management Practice at IIM, Ahmedabad



**Independent Director**

**Rolf Hoffmann**  
Strategic and results-orientated Executive with expertise in creating and optimizing commercial opportunities in all global markets

# Key Financials



# Summary Financials



Market capitalisation Rs 4,235 Bn / US\$47 Bn (as of 18<sup>th</sup> Dec 2025)

( All Figures in Rs mn )

P&L Summary	FY21	YoY	FY22	YoY	FY23	YoY	FY24	YoY	FY25	YoY
Sales	332,331	3%	384,264	16%	432,789	13%	477,585	10%	520,412	9%
Gross Profit	245,430	6%	280,749	14%	326,167	16%	370,958	14%	412,939	11%
EBITDA	82,263	27%	101,697	24%	116,468	15%	130,231	12%	152,717	17%
Net Profit	29,038	-23%	32,727	13%	84,736	159%	95,764	13%	109,290	14%
Net Profit (Adjusted)	59,317 <sup>#</sup>	47%	76,671 <sup>#</sup>	29%	86,450 <sup>#</sup>	13%	100,707 <sup>#</sup>	16%	119,844 <sup>#</sup>	19%
R&D Spend	21,499	9%	22,194	3%	23,676	7%	31,776	34%	32,484	2%

BS Summary	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Shareholders Funds	464,628	480,112	559,954	636,668	722,180
Loan Funds	35,235	9,307	61,979	28,457	18,696
Net Fixed Assets	168,322	173,607	206,806	200,330	202,908
Investments	96,125	128,486	148,301	150,258	150,258
Cash and Bank Balances	64,455	50,334	57,703	105,207	113,316
Inventory	89,970	89,251	105,131	98,683	102,433
Sundry Debtors	90,614	104,846	114,385	112,494	130,461
Sundry Creditors	39,737	44,898	56,815	56,533	61,843

# FY21 - Adjusted for Rs 30.3 Bn provision (related to Taro US – DOJ & MDL settlement Rs 42.2 Bn, Rs 0.9 Bn provision related to UK Citalopram case, Rs 4.1 Bn related to deferred tax gain. Taro provisions are adjusted for minority interest)

# FY22 - Adjusted for Rs 43.9 Bn provision (for US litigation related to Ranbaxy Meijer & Others Rs 39,357 mn, Japan (plant) loss Rs 382 mn, Dexasite impairment Rs 1,503 mn., US MDL (Taro) Rs 3,465 mn (after adjusting for Taro minority of Rs 960 mn) & Deferred Tax gain = Rs 5,178 mn offset by MAT Credit reversal of Rs 4,410 mn).

# FY23 - Adjusted for Rs 1.7 Bn provision related to (i) Medinstill Impairment =Rs. 1,644 mn (ii) Concert acquisition =Rs. 644 mn (iii) Income from Onerous Contract (SATO) =Rs. 574 mn

# FY24 - Adjusted for Rs 4.9 Bn provision related to (i) Impairment of intangible under development of Ache Labs = Rs. 1,492 mn (ii) Nigeria Forex loss =Rs. 2,014 mn (iii) Alchemee restructuring cost =Rs. 507 mn (iv) Lipitor West Virginia settlement = Rs 698 mn, (v) Japan restructuring cost = Rs 232 mn.

# FY25 - Adjusted for Rs 10.6 Bn provision related to (i) Opioid settlement = Rs 3,162 mn (ii) Concert Restructuring =Rs 440 mn (iii) Taro Restructuring =Rs 580 mn (iv) Investment in Lyndra =Rs 2,597 mn (v) Deferred tax adjustments =Rs 3,775 mn

# Sales split



In Rs Bn

Sales


332

384

433

478

520



■ India Formulations

■ US Formulations

■ Emerging Markets

■ Rest of World

■ API+Others

# EBITDA trend



In Rs Bn

Sales

332

384

433

478

520

% of Sales

26.1%

20.6%

28.5%

25.3%

26.9%

19.0%

28.0%

26.9%

24.6%

19.2%

30.4%

26.5%

22.3%

19.7%

32.3%

26.9%

20.7%

19.2%

32.2%

29.0%

FY21

FY22

FY23

FY24

FY25

EBITDA

Other Expenditure


Personnel Costs

Material Costs


# Cash Flow & debt




## Net Cash from Operating Activities (Rs Bn)




## Free Cash Flow (Rs Bn)



## Gross Debt (Rs Bn)



## Net Cash (excluding debt) (Rs Bn)



# Financial ratios



	FY21	FY22	FY23	FY24	FY25
<b>Growth (%)</b>					
Sales	2.8	15.6	12.6	10.4	9.0
Gross Profit	6.3	14.4	16.2	13.7	11.3
EBITDA	21.5	22.5	12.0	11.8	17.3
Net Profit	(22.9)	12.7	158.9	13.0	14.1
Net Profit (Adjusted)	47.4 <sup>#</sup>	29.3 <sup>#</sup>	12.8 <sup>#</sup>	16.5 <sup>#</sup>	19.0 <sup>#</sup>
<b>Margins (%)</b>					
Gross Margin	73.9	73.1	75.4	77.7	79.3
EBITDA Margin (%)	25.3	26.9	26.5	26.9	29.0
Net Margin	8.7	8.5	19.3	19.7	20.8
Net Margin (Adjusted)	17.7 <sup>#</sup>	19.8 <sup>#</sup>	19.7 <sup>#</sup>	20.8 <sup>#</sup>	22.8 <sup>#</sup>
<b>Return (%)</b>					
ROCE	13.5	16.5	16.5	18.2	20.5
ROE	12.5	15.0	15.9	16.7	17.4
<b>Others</b>					
Fully Diluted EPS	12.1	13.6	35.3	39.9	45.6
Fully Diluted EPS (Adjusted)	24.7 <sup>#</sup>	32.0 <sup>#</sup>	36.0 <sup>#</sup>	42.0 <sup>#</sup>	49.9 <sup>#</sup>
<b>R&amp;D Spend % of Net Sales</b>					
Revenue	6.5	5.8	5.5	6.7	6.2
Capital	6.4	5.6	5.4	6.6	6.1
Capital	0.1	0.2	0.1	0.1	0.1

# FY21 - Adjusted for Rs 30.3 Bn provision (related to Taro US – DOJ & MDL settlement Rs 42.2, Rs 0.9 Bn provision related to UK Citalopram case, Rs 4.1 Bn related to deferred tax gain. Taro provisions are adjusted for minority interest)

# FY22 - Adjusted for Rs 43.9 Bn provision (for US litigation related to Ranbaxy Meijer & Others Rs 39,357 mn, Japan (plant) loss Rs 382 mn, Dexasite impairment Rs 1,503 mn., US MDL (Taro) Rs 3,465 mn (after adjusting for Taro minority of Rs 960 mn) & Deferred Tax gain = Rs 5,178 mn offset by MAT Credit reversal of Rs 4,410 mn)

# FY23 - Adjusted for Rs 1.7 Bn provision related to (i) Medinstill Impairment =Rs. 1,644 mn (ii) Concert acquisition =Rs. 644 mn (iii) Income from Onerous Contract (SATO) =Rs. 574 mn

# FY24 - Adjusted for Rs 4.9 Bn provision related to (i) Impairment of intangible under development of Ache Labs = Rs. 1,492 mn (ii) Nigeria Forex loss =Rs. 2,014 mn (iii) Alchemee restructuring cost =Rs. 507 mn (iv) Lipitor West Virginia settlement = Rs 698 mn, (v) Japan restructuring cost = Rs 232 mn.

# FY25 - Adjusted for Rs 10.6 Bn provision related to (i) Opioid settlement = Rs 3,162 mn (ii) Concert Restructuring =Rs 440 mn (iii) Taro Restructuring =Rs 580 mn (iv) Investment in Lyndra =Rs 2,597 mn (v) Deferred tax adjustments =Rs 3,775 mn

# Key Financials Q2 FY26



( All Figures in Rs mn )

	Q2 FY26	Q2 FY25	CHANGE	H1FY26	H1FY25	CHANGE
Gross Sales	144,052	132,642	8.6%	281,913	257,887	9.3%
Revenue from operation	144,783	132,914	8.9%	283,297	259,441	9.2%
Gross Profit	114,225	105,700	8.1%	223,938	204,191	9.7%
Gross Margin	79.3%	79.7%		77.7%	75.4%	
EBITDA	45,271	39,390	14.9%	88,287	75,466	17.0%
EBITDA Margin	31.3%	29.6%		26.9%	26.5%	
Net Profit	31,180	30,402	2.6%	53,966	58,758	-8.2%
Net margin	21.5%	22.9%		20.8%	19.7%	
Net Profit (Adjusted)	31,180	30,402	2.6%	61,141 <sup>#</sup>	58,758	4.1%
Net margin (Adjusted)	21.5%	22.9%		22.8%	20.8%	
R&D	7,827	7,929	-1.3%	16,855	15,869	6.2%
R&D as % of Net Sales	5.4%	6.0%		6.2%	6.7%	
EPS (Diluted) INR	13.0	12.7	2.6%	22.5	24.5	-8.2%
EPS (Diluted) INR (Adjusted)	13.0	12.7	2.6%	25.5 <sup>#</sup>	24.5	4.1%

**Net Profit Adjustment:**

# H1FY26 - Adjusted for Rs 7.2 Bn related to the (i) SCD- 044 impairment Rs 2,870 mn, (ii) GxMDL cost Rs 5,310 mn, (iii) Benefit from deferred tax adjustment Rs 1,005 mn


# Sales split Q2 FY26



( All Figures in Rs mn )

	Q2 FY26	Q2 FY25	CHANGE	H1FY26	H1FY25	CHANGE
<b>Formulation</b>						
India	47,348	42,652	11.0%	94,559	84,097	12.4%
US	43,288	43,274	0.0%	83,740	82,169	1.9%
Emerging Markets	28,367	24,519	15.7%	53,898	48,215	11.8%
ROW #	20,415	16,633	22.7%	39,151	32,446	20.7%
<i>Sub-total</i>	<b>139,418</b>	<b>127,078</b>	<b>9.7%</b>	<b>271,348</b>	<b>246,926</b>	<b>9.9%</b>
API	4,299	5,338	-19.5%	9,702	10,284	-5.7%
Others	336	226	48.5%	863	677	27.3%
<b>Gross Sales</b>	<b>144,052</b>	<b>132,642</b>	<b>8.6%</b>	<b>281,913</b>	<b>257,887</b>	<b>9.3%</b>

- US Formulations
- India Branded Generics
- Emerging Markets
- Rest of World
- API & Others




# ROW includes Western Europe, Canada, Japan, Australia, New Zealand, Israel and other markets



# Company history and key deals



# Creating a global company over time



# Key deals & rationale



Year	Deals	Country	Rationale
2025	Checkpoint Therapeutics Inc.	Global	First and only US FDA-approved anti-PD-L1 treatment for metastatic or locally advanced (cSCC)
2024	Completed Taro merger	Israel	Acquired outstanding shares of Taro, now a 100% subsidiary of Sun
2024	In-licensed Fibromun	Global	Innovative anti-cancer immunotherapy for the treatment of soft tissue sarcoma and glioblastoma.
2023	In-licensed Nidlegy™	Europe, ANZ	New anti-cancer biopharmaceutical for the treatment of melanoma and non-melanoma skin cancers
2023	Acquired Concert Pharmaceuticals, Inc.	Global	Add a late-stage Innovative product to dermatology franchise. Treatment of alopecia areata
2023	In-licensed Sezaby	US	Addition of product to the Innovative portfolio. Treatment of neonatal seizures
2022	Acquired Uractiv Portfolio from Fiterman Pharma	Romania	Expand non-prescription product basket in Romania and neighbouring markets
2022	In-licensing agreement to expand Winlevi	Japan, ANZ, Brazil, Mexico & Russia	Increase access to new markets for Winlevi
2022	Taro (Sun's subsidiary) acquired Alchemee Business from Galderma	US, Japan & Canada	Acquired the "Proactiv", "Restorative Elements" and "In Defense of Skin" brands. Strengthens Taro's OTC portfolio
2021	In-licensing agreement for Winlevi	US & Canada	Add an Innovative product to dermatology franchise. Topical treatment of acne vulgaris
2020	Exclusive Out-licensing agreement with Hikma for Illumya	Middle East & North Africa	Registration and commercialization of the product in all Middle East & North Africa (MENA) markets.
2020	In-licensing agreement with SPARC for SCD-044	Global	Potential indication in psoriasis, atopic dermatitis & other auto-immune disorders

# Key deals & rationale



Year	Deals	Country	Rationale
2019	Out-licensing agreement with AstraZeneca UK for ready-to-use infusion oncology products	Mainland China	Commercialise oncology portfolio in Mainland China
2019	Licensing agreement with CMS for tildrakizumab, Cequa & 8 generic products	Greater China	Access to Greater China market
2018	Acquired Pola Pharma in Japan	Japan	Access to Japanese dermatology market
2016	Acquired rights for Cequa & Odomzo	Global	Enhance Innovative Medicines pipeline. Treatment of dry eye and locally acting Basal Cell Carcinoma respectively
2016	Acquired Biosintez	Russia	Local manufacturing capability to enhance presence in Russian market
2016	Out-licensing agreement with Almirall for tildrakizumab	Europe	Access to European market for tildrakizumab
2016	Acquired 14 brands from Novartis	Japan	Entry into Japan
2015	Sun Pharma – Ranbaxy Merger	Global Markets	Strengthen position in the Global generic Pharma industry, Creating largest Pharma company in India with strong positioning in Emerging Markets
2014	In-licensing agreement with Merck for tildrakizumab	Global Markets	Strengthen the Innovative product pipeline. Treatment of plaque psoriasis
2014	Acquired Pharmalucence	US	Access to sterile injectable capacity in the US
2012	Acquired DUSA Pharma, Inc.	US	Access to Innovative drug-device combination in dermatology segment
2010	Acquired Taro Pharmaceutical Industries Ltd.	Israel	Access to dermatology generic portfolio Manufacturing facilities at Israel & Canada
1997	Acquired Caraco	US	Entry into US Market

# Sun Pharma - focus areas



## US business

- Enhance share of innovative/branded business
- Continue to focus on complex generics and high entry barrier segments
- Ensure broad product offering to customers across multiple dosage forms

## India business

- Focus on productivity enhancement
- Maintain leadership position in a fiercely competitive market
- Continuously innovate to ensure high brand equity with doctors
- Continue to evaluate in-licensing opportunities for latest generation patented products

## EM & RoW business

- Gain critical mass in key markets
- Enhance innovative product basket in Emerging Markets
- Focus on profitable growth

## Global Consumer Healthcare

- Maintain leadership in existing markets through focus on innovative solutions
- Enhance presence in high growth markets

# Sun Pharma - focus areas



## Sustainability

- Unwavering focus on sustainability, built on a legacy rooted in caring for people, communities and the planet.
- Committed to governance, community upliftment, access to affordable healthcare & environment conservation

## R&D

- Focus on developing complex products across multiple dosage forms
- Invest to further build the Innovative Medicines pipeline

## Regulatory/ Quality

- Ensuring 24x7 compliance to cGMP
- Continuously enhance systems, processes, human capabilities to ensure compliance with global regulatory standards

## Financial

- Target mid to high single digit consolidated topline growth for FY26
- Focus on sustainable and profitable growth
- Focus on improving overall return ratios

# Sun Pharma at a glance



## Leading global specialty generic company

### Global presence

Operates in over 100 countries

### Diversified business

Innovative Medicines, branded generics, generics & APIs

### Innovative Medicines

Fast growing. Focused therapy approach.

### US Generics

13<sup>th</sup> largest in US generics market##

### India

Largest pharma company in India\*\*

### Emerging Markets

Operating at scale in over 80 countries

### Rest of World

Expanding presence in Ex-US developed markets

### R&D

Global clinical trials. Early-stage novel R&D. Generic R&D

### 40 Manufacturing facilities

Manufacturing capabilities across injectables, sprays, ointments, creams, liquids, tablets and capsules

### Quality compliance

Several facilities approved by global regulators incl. USFDA

### Employees

43,000+ global employee base

## Source: IQVIA data for 12 months ended Oct 2025

\*\* As per AIOCD AWACS data for 12 months ended Sept 2025



## **For more information please contact**

### **Investors**

**Dr. Abhishek Sharma**

Tel : +91 22 4324 4324, Xtn 2929

Tel Direct +91 22 4324 2929

[abhi.sharma@sunpharma.com](mailto:abhi.sharma@sunpharma.com)

### **Corporate Address**

**SUN HOUSE**, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063

© 2017 Sun Pharmaceutical Industries Limited., All Rights Reserved.

"SUN Pharma", The Sun Pharmaceutical Industries Logo are trademarks of Sun Pharmaceutical Industries Limited.

This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

NSE:SUNPHARMA, BSE: 524715, Reuters: SUN.BO, Bloomberg: SUNP IN

CIN: L24230GJ1993PLC019050

[www.sunpharma.com](http://www.sunpharma.com)